In the latest close session, Moderna (MRNA) was down 3.45% at $42.55. The stock's change was less than the S&P 500's daily ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

The pharmaceutical sector continues to attract investor attention, with recent clinical developments highlighting the industry’s innovation potential. Moderna (MRNA) emerged as the top-performing ...

The vaccine maker is expanding beyond its COVID-focused offerings.

Shares of Moderna MRNA rose 13% in the past week after the company announced preliminary sales for the full-year 2025, as ...

Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading this week, for the July 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the ...

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 across the United States, European Union, Canada and Australia. These filings ...